Accelerate

• India's Bharatiya Janata Party (BJP), in power since 2014, has captured independent institutions like the Election Commission, judiciary, and media, leading to democratic backsliding into a hybrid regime. • After winning 240 seats in the 2024 Lok Sabha elections—short of the 272 majority—Prime Minister Narendra Modi rapidly passed a citizenship law targeting Muslims as a key poll promise amid strong partisan support. • Legislative capture has weakened checks and balances, turning parliament into a rubber stamp through censorship, intimidation, and power centralization.

• Cerebras, a leading AI chipmaker, announced plans to raise up to $3.5 billion through an initial public offering (IPO). • The fundraising effort signals strong market confidence in specialized AI chip manufacturers as enterprises scale artificial intelligence infrastructure deployments. • Going public positions Cerebras to compete aggressively with established semiconductor giants while investing in next-generation AI computing architecture.

• US GDP expanded at a 2.0% annualized rate in Q1 2026, rebounding from 0.5% in the prior quarter, driven by government spending, exports, and investment. • Consumer spending stayed strong in March, bolstered by rising personal income and consumption. • Manufacturing PMI hit its strongest since May 2022 per S&P Global, though possibly due to inventory buildup rather than demand.

• Broadcom provided second-quarter guidance of $9.2 billion in revenues, exceeding analyst estimates by 6%, driven by surging demand for data center semiconductors and artificial intelligence accelerators from cloud computing providers. • CEO Hock Tan stated that AI-related semiconductor orders are tracking 40% above historical averages, with major customers committing to long-term capacity agreements through 2028, signaling sustained strong demand. • The robust guidance helped lift semiconductor index ETFs 2.1% during extended trading and sparked upgrades from multiple analysts who raised price targets on Broadcom by 8–12% based on improved visibility into AI infrastructure spending cycles.

• President Trump issued an Executive Order directing the Department of Health and Human Services to expedite access to treatments for patients with serious mental illness. • The FDA is accelerating its review process for mental health therapies in response to the directive. • This policy shift aims to reduce barriers to treatment approval and expand therapeutic options for affected patients.

• A comprehensive analysis from the National Center for Atmospheric Research shows US carbon dioxide emissions fell 8.2% year-over-year in Q1 2026, driven primarily by renewable energy sources now supplying 34% of national electricity generation. • Solar and wind capacity additions reached record levels with 42 gigawatts of new renewable infrastructure installed in 2025, according to data released by the Department of Energy and independent research institutions. • Climate scientists attribute the acceleration partly to state-level climate policies and federal incentives from the 2024 Clean Energy Investment Act, though transportation and industrial sectors still require significant emission reductions.

• President Trump signed an executive order directing federal regulators to fast-track FDA review of psychedelic drugs including psilocybin and ibogaine for treating depression, anxiety, and PTSD. • The order allocates $50 million in federal funds to states implementing or developing psychedelic treatment programs as part of a federal-state partnership initiative. • Trump highlighted that over 14 million American adults have serious mental illness, with approximately 8 million on prescription medication, framing psychedelics as addressing a national mental health crisis including suicide prevention.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.